AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02495623 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01243775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belotaxel
Description: 60 mg/m2 3 weekly (day 1)
Study NCT01243775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belloxa
Description: 70 mg/m2 3 weekly (day 2)
Study NCT03916783 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combination intervention
Description: The FDA will be a matched savings account held in the child's name with the parent or caregiver as the co-signer, in a financial institution registered by the Central Bank (Bank of Uganda). The account opened will be matched with money from the program up to a match cap of 72,000 Uganda shillings (an equivalent of $20) a month per family for the 9-month intervention period.~The FDAs will be complemented with four sessions of Financial Literacy and Management (FL\&M) and two sessions of cancer education conducted over a 4-week period. The two cancer-specific education sessions will use UCI materials to address: 1) definitions of cancer, potential causes, signs and symptoms, and importance of cancer testing; 2) debunking cultural explanations for the causes of cancer and misconceptions (beliefs, values, norms and prevailing attitudes)regarding cancer that largely impede service use.
Study NCT00264550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg
Description: Participants will receive subcutaneous (SC) injections of golimumab 100 mg every 4 weeks.
Study NCT00264550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg
Description: Participants will receive subcutaneous (SC) injections of golimumab 50 mg every 4 weeks.
Study NCT00264550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Participants will receive methotrexate capsules weekly.
Study NCT00264550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Participants will receive methotrexate capsules weekly.
Study NCT00264550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: Participants will receive subcutaneous (SC) injections of placebo every 4 weeks.
Study NCT01959594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg PF-06412562
Description: oral dosing of 10 mg PF-06412562 tablets three times a day for 14 days
Study NCT01959594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 mg PF-06412562
Description: oral dosing of 25 mg PF-06412562 tablets three times a day for 14 days
Study NCT00264550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsules
Description: Participants will receive placebo capsules weekly
Study NCT01794559 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEER Interactive Report
Description: The PEER Interactive Report provides information comparing the subject's Quantitative Electroencephalography (QEEG) to a database of outcomes from patients with similar QEEG results, and how they responded to on-label treatments. This report provides a probability of how this subject will respond to treatment based upon a comparison of similar subjects in the database.
Study NCT05026372 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Gratitude (MG)
Description: The interventionist will review the tools the couples had learned over the course of this program and help them proactively identify strategies to continue to implement them into their lives. Couples will receive instructions on how to continue with this program when no longer meeting with the interventionist.
Study NCT01959594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06412562 TBD mg
Description: oral dosing of PF-06412562 tablets three times a day for 14 days. Dosage and frequency to-be-determined based on previous cohorts
Study NCT02926690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTS167PO
Description: Single arm, no competitor
Study NCT05026372 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Value-Based Living (MV)
Description: The interventionist will review the tools the couples had learned over the course of this program and help them proactively identify strategies to continue to implement them into their lives. Couples will receive instructions on how to continue with this program when no longer meeting with the interventionist.
Study NCT03703310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patidegib Topical Gel, 2%
Description: Patidegib Topical Gel, 2%
Study NCT03703310 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Patidegib Topical Gel, Vehicle
Description: Patidegib Topical Gel, Vehicle
Study NCT02811913 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: 3 types of interventions on different sessions~* session 1 - High frequency rTMS targeting contralesional sensory cortex~* session 2 - Low frequency rTMS~* session 3 - sham rTMS
Study NCT02811913 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: peripheral sensory stimulation
Description: peripheral sensory electrical stimulation and vibration of the stroke-affected hand administered concurrently with each rTMS
Study NCT04104685 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: FCD105
Description: Experimental combination
Study NCT04104685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3% Minocycline Foam
Description: Active Comparator
Study NCT04104685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.3% Adapalene Foam
Description: Active Comparator
Study NCT04104685 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Foam
Description: Placebo
Study NCT02969096 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Targeted Cryoablation Therapy
Description: A cryoprobe is inserted percutaneously under CT guidance into the targeted lesion. Patients undergo ablation using a freeze-thaw-freeze cycle lasting approximately 6-10-6 or 8-10-8 minutes, respectively.
Study NCT03315338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT118335, 25 mg
Description: CORT118335 is supplied as capsules for oral dosing
Study NCT03315338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone Oral Tablet
Description: Challenge Agent, Dose and Route of Administration:~Standard release 1x20mg and 1x5mg (25mg total) dose, orally administered.
Study NCT03315338 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone Oral Tablet
Description: Challenge Agent, Dose and Route of Administration:~Standard release 1x20mg and 1x5mg (25mg total) dose, orally administered.
Study NCT03315338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose
Description: 75 g in 300 mL solution, orally administered
Study NCT03315338 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucose
Description: 75 g in 300 mL solution, orally administered
Study NCT03315338 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral suspension
Description: Reference Therapy, Dose and Route of Administration:~Placebo suspension, orally administered.
Study NCT02223611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1 capsule
Description: Within four weeks after the completely resection, S-1 was administered orally twice a day, after meals on days 1 to 14. The actual dose of S-1 was selected as follows: in a patient with body surface area (BSA)\<1.25 m2 40mg twice a day, 1.25 m2≤BSA\<1.5 m2 50mg twice a day, and 1.5 m2≤BSA 60mg twice a day. Cisplatin (75 mg/m2) was administered intravenously on day 1 The treatment regimen was repeated every 3 weeks, totally 4 cycles unless disease progression or unacceptable toxicity occurred.
Study NCT02223611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Vinorelbine (25 mg/m2) is administered intravenously on day 1, and day 8. Cisplatin (75 mg/m2) is administered intravenously on day 1. The treatment regimen is repeated every 3 weeks, totally 4 cycles unless disease progression or unacceptable toxicity occurred.
Study NCT03315338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT118335, 75mg
Description: CORT118335 is supplied as capsules for oral dosing
Study NCT03315338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT118335, 225mg
Description: CORT118335 is supplied as capsules for oral dosing
Study NCT03315338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT118335, 675mg
Description: CORT118335 is supplied as capsules for oral dosing
Study NCT00258128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salsalate
Description: Active
Study NCT03315338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT118335, 600mg
Description: CORT118335 is supplied as capsules for oral dosing
Study NCT00258128 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for salslate, used only in the third trial
Study NCT03315338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT118335, 630mg
Description: CORT118335 is supplied as capsules for oral dosing
Study NCT03315338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT118335, 375mg
Description: CORT118335 is supplied as capsules for oral dosing
Study NCT04103541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IP-Colombia
Description: The IP-Colombia program is a multi-component intervention carried out in the context of therapeutic camp, based on EDMR therapies and mindfulness-based interventions. Alongside the interventions, activities are done to facilitate healthy lifestyles, empathy, \[and\] the recognition and expression of emotions through exercise, art workshops, musical creation, dance and theater.
Study NCT02462291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ecological Environmental therapy
Description: The program of EET consist of the physical interaction (visual, tactile, olfactory) between natural ecological elements such as flowers, trees, grass, and the patients with AD.
Study NCT04045483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality based cognitive training
Description: The VR-based cognitive training consists of a three-dimensional simulation of home, a mart, bus stop, and street. It provides an integrative cognitive training experience where participants are required to accomplish some common ADL's in three frequently visited places: home, a supermarket, and bus stop.
Study NCT00131131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT02994043 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Based Relapse Prevention Therapy
Description: An 8-week, outpatient psychotherapy that combines mindfulness components with relapse prevention.
Study NCT02994043 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relapse Prevention Therapy
Description: An 8-week, outpatient psychotherapy that uses cognitive-behavioral components to reduce alcohol-related consequences.
Study NCT01233739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate
Description: Administration of 2 capsules of 400 mg of chondroitin sulfate orally.
Study NCT04839848 — intervention group
Intervention type: DEVICE
Intervention: Lichtenstein mesh repair
Description: A groin hernia repair, reinforced by synthetic mesh. The mesh is affixed with sutures
Study NCT01632241 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus standard therapy
Description: Placebo plus standard therapy
Study NCT01632241 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg plus standard therapy
Description: Belimumab 10mg/kg plus standard therapy
Study NCT01632241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard therapy
Description: Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; biologics and intravenous cyclophosphamide are not permitted.
Study NCT01632241 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard therapy
Description: Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; biologics and intravenous cyclophosphamide are not permitted.
Study NCT02024022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard approach
Description: bowel cleansing with either 4L PEG or sodium picosulphate/magnesium citrate
Study NCT02024022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Individualized approach
Study NCT00497237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone plus formoterol fixed combination
Description: 100+6 pMDI
Study NCT00497237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone plus salmeterol fixed combination
Description: diskus 250/50
Study NCT02836873 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bexagliflozin
Description: Bexagliflozin tablet, 20 mg
Study NCT02836873 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (inactive) tablet to match the active comparator
Study NCT03384316 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-051; adenoviral brachyury vaccine
Description: immunotherapeutic vaccine administered subcutaneously every 3 weeks for 3 doses, and then every 8 weeks for up to a year
Study NCT03384316 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-061; adenoviral Mucin-1 (MUC1) vaccine
Description: immunotherapeutic vaccine administered subcutaneously every 3 weeks for 3 doses, and then every 8 weeks for up to a year
Study NCT03384316 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-011; adenoviral Carcinoembryonic antigen (CEA) vaccine
Description: immunotherapeutic vaccine administered subcutaneously every 3 weeks for 3 doses, and then every 8 weeks for up to a year
Study NCT02610231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istradefylline 20 mg or 40 mg
Description: Istradefylline 20 or 40 mg
Study NCT03034746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity (PA)
Description: It will perform a program consist of 15 min of warm-up, 60 min of aerobic and resistance training, and 15 min of cool-down.
Study NCT03034746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive treatment (CT)
Description: The cognitive stimulation group will received a rehabilitation program with multimodal repetitive stimulation in order to exercise and reinforce the cognitive skills of the participant to slow/prevent the decline. In particular the treatment will be focused on reorient the patient about his/her-self, his/her history and his/her environment, to improve the memory skill by teaching compensatory and restitutive strategies, to help the patient to the discussion about everyday life and in particular to the everyday problems
Study NCT01389895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 557
Description: AMG 557 (210 mg) or (140 mg ) will be administered as subcutaneous injections in the anterior abdomen of the subjects. Twelve subjects will be randomized to receive AMG 557. Beginning on Day 1, subjects will receive either 210 mg AMG 557 or 140 mg AMG 557 once weekly for 3 weeks on Day 1, Day 8, and Day 15 and following with 6 additional doses of AMG 557 every other week on Day 29, Day 43, Day 57, Day 71, Day 85, and Day 99. Subjects will be followed out to Day 253 for safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) assessments.
Study NCT01389895 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AMG 557 Placebo
Description: AMG 557 Placebo (210 mg) or (140 mg )will be administered as subcutaneous injections in the anterior abdomen of the subjects. Twelve subjects will be randomized to receive placebo. Beginning on Day 1, subjects will receive placebo once weekly for 3 weeks on Day 1, Day 8, and Day 15 and following with 6 additional doses of placebo every other week on Day 29, Day 43, Day 57, Day 71, Day 85, and Day 99. Subjects will be followed out to Day 253 for safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) assessments.
Study NCT03315338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT118335, 100mg
Description: CORT118335 is supplied as a suspension for oral dosing
Study NCT03315338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT118335, 300mg
Description: CORT118335 is supplied as a suspension for oral dosing
Study NCT03315338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT118335, 900mg
Description: CORT118335 is supplied as a suspension for oral dosing
Study NCT01233739 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of 2 capsules of placebo orally.
Study NCT03315338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT118335, 150mg
Description: CORT118335 is supplied as a suspension for oral dosing
Study NCT03315338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT118335, 1500mg
Description: CORT118335 is supplied as a suspension for oral dosing
Study NCT03315338 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo capsules, orally administered
Study NCT02929901 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: caffeine and chlorogenic acid
Description: caffeine plus chlorogenic acid
Study NCT02929901 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: caffeine
Description: caffeine plus placebo
Study NCT00013091 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Self-management therapy; Psychoeducational group therapy
Study NCT02929901 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: chlorogenic acid
Description: chlorogenic acid plus placebo
Study NCT02929901 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo plus placebo
Study NCT02516826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Study NCT02516826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan
Study NCT03502434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM04755
Description: Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.
Study NCT02516826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination
Description: Rosuvastatin/Olmesartan(Combination)
Study NCT02516826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Rosuvastatin
Study NCT02516826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Olmesartan
Study NCT02516826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Rosuvastatin/Olmesartan(Combination)
Study NCT00977938 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo & Aspirin
Study NCT00977938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel & Aspirin, Prasugrel & Aspirin
Study NCT04175522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunoglobulin G
Description: IGIV 10%(400mg/kg) QD for 5 consecutive days administrated intravenously.
Study NCT04175457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-cigarette
Description: E-cigarette inhalation for 30 minutes using e-cigarette with and without nicotine
Study NCT04175457 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: e-cigarette
Description: E-cigarette inhalation for 30 minutes using e-cigarette with and without nicotine
Study NCT02523625 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound of temporal and axillary arteries
Description: Each patient will have a clinical assessment and ultrasound examination of both temporal and axillary arteries
Study NCT03502434 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Vehicle
Description: Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.
Study NCT03502434 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: White Petrolatum
Description: Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.
Study NCT03502434 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sodium lauryl sulfate
Description: Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.